CoChat
Sign Up
Cited by 48

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis

Barocas, Joshua A, Morgan, Jake R, Wang, Jianing, McLoone, Dylan, Wurcel, Alysse, Stein, Michael D·2021·Clinical Infectious Diseases
DOI 10.1093/cid/ciaa062
Open this paper in CoChat — free account

Abstract

Background: Endocarditis, once predominately found in older adults, is increasingly common among younger persons who inject drugs. Untreated opioid use disorder (OUD) complicates endocarditis management. We aimed to determine if rates of overdose and rehospitalization differ between persons with OUD with endocarditis who are initiated on medications for OUD (MOUDs) within 30 days of hospital discharge and those who are not. Methods: We performed a retrospective cohort study using a large commercial health insurance claims database of persons ≥18 years between July 1, 2010, and June 30, 2016. Primary outcomes included opioid-related overdoses and 1-year all-cause rehospitalization. We calculated incidence rates for the primary outcomes and developed Cox hazards models to predict time from discharge to each primary outcome as a function of receipt of MOUDs. Results: The cohort included 768 individuals (mean age 39 years, 51% male). Only 5.7% of people received MOUDs in the 30 days following hospitalization. The opioid-related overdose rate among those who did receive MOUDs in the 30 days following hospitalization was lower than among those who did not (5.8 per 100 person-years [95% confidence interval [CI], 5.1–6.4] vs 7.3 per 100-person years [95% CI, 7.1–7.5], respectively). The rate of 1-year rehospitalization among those who received MOUDs was also lower than those who did not (162.0 per 100 person-years [95% CI, 157.4–166.6] vs 255.4 per 100 person-years [95% CI, 254.0–256.8], respectively). In the Cox hazards models, the receipt of MOUDs was not associated with either of the outcomes. Conclusions: MOUD receipt following endocarditis may improve important health-related outcomes in commercially insured persons with OUD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa062

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 37

  1. 2017, Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health
  2. CDC, 2011, Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008, MMWR Morb Mortal Wkly Rep, 60, 1487
  3. Fleischauer, 2017, Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence—North Carolina, 2010–2015, MMWR Morb Mortal Wkly Rep, 66, 569, 10.15585/mmwr.mm6622a1 · DOI
  4. Gray, 2018, Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study, BMC Infect Dis, 18, 532, 10.1186/s12879-018-3408-y · DOI
  5. Miller, 2019, Many opportunities to record, diagnose, or treat injection drug-related infections are missed: a population-based cohort study of inpatient and emergency department settings, Clin Infect Dis, 68, 1166, 10.1093/cid/ciy632 · DOI
  6. Wurcel, 2016, Increasing infectious endocarditis admissions among young people who inject drugs, Open Forum Infect Dis, 3, ofw157, 10.1093/ofid/ofw157 · DOI
  7. Ciccarone, 2016, Nationwide increase in hospitalizations for heroin-related soft tissue infections: associations with structural market conditions, Drug Alcohol Depend, 163, 126, 10.1016/j.drugalcdep.2016.04.009 · DOI
  8. Ronan, 2016, Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12, Health Aff (Millwood), 35, 832, 10.1377/hlthaff.2015.1424 · DOI
  9. Collier, 2018, Using population based hospitalization data to monitor increases in conditions causing morbidity among persons who inject drugs, J Community Health, 43, 598, 10.1007/s10900-017-0458-9 · DOI
  10. Rudasill, 2019, Clinical outcomes of infective endocarditis in injection drug users, J Am Coll Cardiol, 73, 559, 10.1016/j.jacc.2018.10.082 · DOI
  11. Volkow, 2014, Medication-assisted therapies: tackling the opioid-overdose epidemic, N Engl J Med, 370, 2063, 10.1056/NEJMp1402780 · DOI
  12. Mattick, 2014, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, Cochrane Database Syst Rev, CD002207
  13. Kampman, 2015, American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use, J Addict Med, 9, 358, 10.1097/ADM.0000000000000166 · DOI
  14. Hedrich, 2012, The effectiveness of opioid maintenance treatment in prison settings: a systematic review, Addiction, 107, 501, 10.1111/j.1360-0443.2011.03676.x · DOI
  15. Larney, 2014, Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study, BMJ Open, 4, e004666, 10.1136/bmjopen-2013-004666 · DOI
  16. Rosenthal, 2016, Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis, Am J Med, 129, 481, 10.1016/j.amjmed.2015.09.024 · DOI · Paper page
  17. Liebschutz, 2014, Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial, JAMA Intern Med, 174, 1369, 10.1001/jamainternmed.2014.2556 · DOI
  18. Cunningham, 2006, Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital, Fam Med, 38, 336
  19. Hassamal, 2017, Overcoming barriers to initiating medication-assisted treatment for heroin use disorder in a general medical hospital: a case report and narrative literature review, J Psychiatr Pract, 23, 221, 10.1097/PRA.0000000000000231 · DOI
  20. Winetsky, 2018, Expanding treatment opportunities for hospitalized patients with opioid use disorders, J Hosp Med, 13, 62, 10.12788/jhm.2861 · DOI
  21. Shanahan, 2010, A transitional opioid program to engage hospitalized drug users, J Gen Intern Med, 25, 803, 10.1007/s11606-010-1311-3 · DOI
  22. Velez, 2017, “It’s been an experience, a life learning experience”: a qualitative study of hospitalized patients with substance use disorders, J Gen Intern Med, 32, 296, 10.1007/s11606-016-3919-4 · DOI
  23. Naeger, 2016, Post-discharge treatment engagement among patients with an opioid-use disorder, J Subst Abuse Treat, 69, 64, 10.1016/j.jsat.2016.07.004 · DOI
  24. Morgan, 2019, Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort, Drug Alcohol Depend, 200, 34, 10.1016/j.drugalcdep.2019.02.031 · DOI · Paper page
  25. Hadland, 2018, Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder, JAMA Pediatr, 172, 1029, 10.1001/jamapediatrics.2018.2143 · DOI
  26. Schranz, 2018, Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data, Ann Intern Med, 170, 31, 10.7326/M18-2124 · DOI
  27. Tsui, 2018, Utilization of buprenorphine and methadone among opioid users who inject drugs, Subst Abus, 39, 83, 10.1080/08897077.2017.1363844 · DOI
  28. Zoorob, 2019, Fentanyl shock: the changing geography of overdose in the United States, Int J Drug Policy, 70, 40, 10.1016/j.drugpo.2019.04.010 · DOI · Paper page
  29. Soeffing, 2009, Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year, J Subst Abuse Treat, 37, 426, 10.1016/j.jsat.2009.05.003 · DOI
  30. Barocas, 2019, Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids, Int J Drug Policy, 72, 160, 10.1016/j.drugpo.2019.05.010 · DOI
  31. Gutkind, 2019, Cost-effectiveness of HCV treatment models for people who inject drugs in opioid agonist treatment programs, Clin Infect Dis
  32. Altice, 2011, HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study, J Acquir Immune Defic Syndr, 56, S22, 10.1097/QAI.0b013e318209751e · DOI
  33. Feder, 2017, Trends in insurance coverage and treatment among persons with opioid use disorders following the Affordable Care Act, Drug Alcohol Depend, 179, 271, 10.1016/j.drugalcdep.2017.07.015 · DOI · Paper page
  34. McKenna, 2017, Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA, Drug Alcohol Depend, 179, 87, 10.1016/j.drugalcdep.2017.06.028 · DOI
  35. Peterson, 2018, US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011–2015, J Subst Abuse Treat, 92, 35, 10.1016/j.jsat.2018.06.008 · DOI
  36. Samples, 2018, Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees, J Subst Abuse Treat, 95, 9, 10.1016/j.jsat.2018.09.001 · DOI
  37. Saloner, 2017, Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population, Med Care, 55, 669, 10.1097/MLR.0000000000000727 · DOI

Cited by

Sorted by citations

Metadata

Authors
Barocas, J. A., Morgan, J. R., Wang, J., McLoone, D., Wurcel, A., & Stein, M. D.
Affiliations
  • Section of Infectious Diseases, Boston Medical Center (BMC), Boston, Massachusetts, USA
  • Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts, USA
  • Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA
  • Division of Geographic Medicine and Infectious Diseases, Department of Medicine Tufts Medical Center, Boston, Massachusetts, USA
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2020-01-21
Volume
72
Issue
3
Pages
472-478
ISSN
  • 1058-4838
  • 1537-6591
DOI
10.1093/cid/ciaa062
Cited by
48
References
3
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Funders
  • National Institute on Drug Abuse
  • National Institutes of Health (R01DA046527, P30DA040500)
  • Tufts University School of Medicine (KL2TR002545-01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review